SCIENCEHOOD

Research Article

Neurology and Neurological Research

Open access

Maria L. Velasquez *

A Comprehensive Clinical and Diagnostic Review of Neuromuscular Conditions: Patterns, Challenges, and Emerging Therapeutic Approaches

Maria L. Velasquez [1*], Arjun Malhotra [2], Helen J. Brooks. [3]

[1] Department of Neurology, Medica Nova Research Institute, Barcelona, Spain

[2] Department of Clinical Neurophysiology, Apex Medical College, New Delhi, India

[3] Faculty of Health Sciences, University of Sydney, Australia

***Corresponding Author: Maria L. Velasquez,** Department of Neurology, Medica Nova Research Institute, Barcelona, Spain

Citation: Maria L. Velasquez, Arjun Malhotra, Helen J. Brooks. (2024), A Comprehensive Clinical and Diagnostic Review of Neuromuscular Conditions: Patterns, Challenges, and Emerging Therapeutic Approaches; J. Neurology and Neurological Research, 1(3): DOI: SH-NNR-RA-013.

Research Article

Volume 01; Issue 03

Received Date: October 26, 2024

Accepted Date: November 07, 2024

Published Date November 18, 2024

DOI: SH-NNR-RA-013

ABSTRACT

Neuromuscular conditions (NMCs) comprise a broad spectrum of disorders that affect the peripheral nervous system, including the muscles, neuromuscular junction, peripheral nerves, and motor neurons. These disorders often lead to muscle weakness, fatigue, and significant impairment in daily living. This study aimed to provide a clinical and diagnostic overview of common NMCs, assess diagnostic delays, and analyze the impact of early intervention. A retrospective review of 150 cases across three tertiary centers was conducted over a period of 24 months. Results highlighted the prevalence of late-stage diagnoses in conditions such as myasthenia gravis and amyotrophic lateral sclerosis, and emphasized the importance of neurophysiological tests and early rehabilitation strategies. Improved clinical awareness and multidisciplinary management approaches can significantly enhance prognosis and quality of life for patients with NMCs.

KEYWORDS:

Neuromuscular diseases, Myasthenia gravis, Amyotrophic lateral sclerosis, Diagnostic delay, Electromyography, Motor neuron disease, Muscle weakness, Neurophysiology, Rehabilitation

INTRODUCTION:

Neuromuscular conditions (NMCs) are a diverse group of acquired and hereditary disorders characterized by dysfunction in any component of the motor unit. These conditions may affect muscle fibers directly or impair the motor neurons and peripheral nerves that innervate them. The clinical manifestation varies widely, from progressive weakness and muscle atrophy to fatigue, spasticity, or sensory disturbances.

Among the most studied conditions are **amyotrophic lateral sclerosis (ALS)**, **myasthenia gravis (MG)**, **Duchenne muscular dystrophy (DMD)**, and **peripheral neuropathies**. Despite advances in genetic diagnostics and imaging techniques, the average time to diagnosis remains lengthy, often delaying therapeutic intervention. This study investigates patterns of neuromuscular diagnosis and treatment, while highlighting gaps in early detection and care.

MATERIALS AND METHODS

Study Design and Setting

A retrospective, observational study was conducted from January 2022 to December 2023 in three neurology departments located in Spain, India, and Australia. Ethical approval was obtained from each institution's review board.

Population

Patients aged 18 years and above, diagnosed with a neuromuscular disorder based on clinical criteria and confirmed by electrophysiological, serological, or genetic testing, were included. Exclusion criteria comprised incomplete medical records or co-existing severe psychiatric conditions.

Data Collection

Electronic health records were reviewed for demographic data, presenting symptoms, diagnostic modalities used, time from symptom onset to diagnosis, and treatment outcomes. Tools used included:

- Electromyography (EMG)
- Nerve conduction studies (NCS)
- Serum autoantibody tests
- Muscle biopsy (where applicable)

Statistical Analysis

Descriptive statistics were applied for frequency

analysis. Inferential statistics including t-tests and chi-square were used to evaluate diagnostic delays and treatment outcomes. Significance was set at $p < 0.05$.

RESULTS

Among the 150 patients analyzed, the most common diagnoses were:

- **Myasthenia Gravis** (30%)
- **ALS** (25%)
- **Peripheral Neuropathy** (20%)
- **Muscular Dystrophies** (15%)
- **Miscellaneous NMCs** (10%)

The average age at diagnosis was 45.6 years (SD ± 13.2), with a male-to-female ratio of 1.2:1. A significant diagnostic delay was observed in ALS (mean delay: 11.5 months), compared to MG (mean delay: 3.4 months).
Only 36% of patients received a full neurophysiological workup at first presentation, and nearly 42% were initially misdiagnosed with musculoskeletal or psychiatric conditions. Early initiation of physiotherapy correlated with improved self-reported functional scores at 12-month follow-up ($p < 0.05$).

DISCUSSION

This study reveals a concerning delay in the diagnosis of several neuromuscular conditions, particularly motor neuron diseases. Factors contributing to this include non-specific early symptoms, lack of access to specialized testing, and limited clinical awareness among general practitioners.
The role of **electrophysiological testing** (EMG and NCS) remains pivotal for differentiating between neuropathic and myopathic conditions, yet its underuse in early stages is notable. The clinical utility of **serological markers** in MG and **genetic testing** in dystrophies further strengthens the case for standardized diagnostic pathways.
In terms of management, **multidisciplinary care**, involving neurology, physiotherapy, nutrition, and psychological support, was associated with improved outcomes. The findings underscore the necessity

CONCLUSION

Neuromuscular conditions remain a diagnostic and therapeutic challenge in clinical neurology. Delays in diagnosis significantly affect disease progression and quality of life. Enhancing early detection through clinician training, routine use of neurophysiological tools, and integrated care models can lead to better outcomes. Further longitudinal studies are needed to assess the impact of emerging therapies and gene-based treatments.

REFERENCES

1. AANEM. Practice parameter: Electrodiagnostic studies in neuromuscular disease. Neurology. 2020;95(13):570-580.
2. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688–1700.
3. Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.
4. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy. Lancet Neurol. 2010;9(1):77-93.
5. Misulis KE, Head TC. Essentials of Clinical Neurophysiology. Elsevier; 2022.
6. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734-1747.
7. Sletten DM, Low PA. An update on autonomic testing in neuromuscular disorders. Muscle Nerve. 2021;63(1):6-15.
8. McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41(4):500-510.

SCIENCEHOOD

Neurology and Neurological Research

Maria L. Velasquez, Arjun Malhotra, Helen J. Brooks (2024), A Comprehensive Clinical and Diagnostic Review of Neuromuscular Conditions: Patterns, Challenges, and Emerging Therapeutic Approaches; J. Neurology and Neurological Research, 1(3): DOI: SH-NNR-RA-013.